{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:09:15Z","timestamp":1751515755600,"version":"3.41.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To explore the predictability of changes in neovascularization morphology on optical coherence tomography angiography (OCTA) in relation to exudative activity on structural OCT in eyes with neovascular age-related macular degeneration treated with ranibizumab 0.5 mg.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Eighty-five eyes of 85 patients with neovascular age-related macular degeneration, diagnosed less than 1 year before study entry and treated with ranibizumab 0.5 mg, were included in this longitudinal, prospective study. Included eyes had no exudative activity feature at study inclusion and were treated with ranibizumab 0.5 mg in a PRN regimen for the following 9 months. At each study visit, structural OCT and OCTA were performed. Qualitative and quantitative vascular characteristics of macular neovascularization were extracted at each visit and correlated with the presence of exudative activity on OCT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>No significant correlation was found between OCTA (neo)vascular characteristics in the absence of exudation with the presence of exudative activity on structural OCT the following month. Optical coherence tomography angiography's positive predictive value for the overall population was 38.87% (confidence interval [33.8%\u201344.2%]). The negative predictive value of OCTA on the overall population was 60.92%. Interobserver reproducibility of OCTA assessments Cohen's kappa = 0.82.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Although OCTA may not be predictive of imminent exudative activity in neovascular age-related macular degeneration, it brings additional information on macular neovascularization flow and holds potential as a tool for understanding vascular remodeling. Neovascularization remodeling and exudation may be two separate findings in the disease process in neovascular age-related macular degeneration without necessarily having a causal relationship.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004444","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T22:00:16Z","timestamp":1741039216000},"page":"1323-1331","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["CAN CHANGES ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY PREDICT EXUDATIVE ACTIVITY ON OPTICAL COHERENCE TOMOGRAPHY IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION?"],"prefix":"10.1097","volume":"45","author":[{"given":"Eric H.","family":"Souied","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Centre Hospitalier Intercommunal de Cr\u00e9teil, University Paris Est, Cr\u00e9teil, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Amoroso","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Centre Hospitalier Intercommunal de Cr\u00e9teil, University Paris Est, Cr\u00e9teil, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Baillif","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Pasteur 2 Hospital, University Hospital, C\u00f4te d'Azur University, Nice, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Devin","sequence":"additional","affiliation":[{"name":"Monticelli-Paradis Center, Marseille, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital, Nantes, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Colantuono","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Centre Hospitalier Intercommunal de Cr\u00e9teil, University Paris Est, Cr\u00e9teil, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocio","family":"Blanco-Garavito","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Centre Hospitalier Intercommunal de Cr\u00e9teil, University Paris Est, Cr\u00e9teil, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Miere","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Centre Hospitalier Intercommunal de Cr\u00e9teil, University Paris Est, Cr\u00e9teil, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250702","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","article-title":"Age-related macular degeneration is the leading cause of blindness","volume":"291","author":"Bressler","year":"2004","journal-title":"JAMA"},{"key":"R2-20250702","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R3-20250702","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"R4-20250702","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/bjophthalmol-2016-309434","article-title":"Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration","volume":"101","author":"Au","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"R5-20250702","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1097\/IAE.0000000000000836","article-title":"Characterizing the effect of anti-vascular endothelial growth factor therapy on treatment-naive choroidal neovascularization using optical coherence tomography angiography","volume":"35","author":"Muakkassa","year":"2015","journal-title":"Retina"},{"key":"R6-20250702","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000433547","article-title":"Optical coherence tomography angiography during follow up: qualitative and quantitative analysis of mixed type I and II choroidal neovascularization after vascular endothelial growth factor trap therapy","volume":"54","author":"Coscas","year":"2015","journal-title":"Ophthalmic Res"},{"key":"R7-20250702","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1097\/IAE.0000000000000846","article-title":"Optical coherence tomography angiography of time course of choroidal neovascularization in response to anti-angiogenic treatment","volume":"35","author":"Huang","year":"2015","journal-title":"Retina"},{"key":"R8-20250702","first-page":"3751702","article-title":"Optical coherence tomography angiography to distinguish changes of choroidal neovascularization after anti-VEGF therapy: monthly loading dose versus pro Re nata regimen","volume":"2018","author":"Miere","year":"2018","journal-title":"J Ophthalmol"},{"key":"R9-20250702","first-page":"548","article-title":"Vascular remodeling of choroidal neovascularization after anti-vascular endothelial growth factor therapy visualized on optical coherence tomography angiography","volume":"39","author":"Miere","year":"2019"},{"key":"R10-20250702","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ajo.2017.12.005","article-title":"Long-term progression of type 1 neovascularization in age-related macular degeneration using optical coherence tomography angiography","volume":"187","author":"Xu","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R11-20250702","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2015.04.012","article-title":"Optical coherence tomography angiography signs of vascular abnormalization with antiangiogenic therapy for choroidal neovascularization","volume":"160","author":"Spaide","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R12-20250702","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1136\/bjophthalmol-2020-318688","article-title":"Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy","volume":"106","author":"Zarbin","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R13-20250702","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.oret.2020.09.016","article-title":"Understanding the mechanisms of fluid development in age-related macular degeneration","volume":"5","author":"Sharma","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"R14-20250702","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/bjophthalmol-2020-317326","article-title":"Non-neovascular age-related macular degeneration with subretinal fluid","volume":"105","author":"Hilely","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"R15-20250702","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/bjophthalmol-2017-310569","article-title":"Optical coherence tomography angiography reproducibility of lesion size measurements in neovascularage-related macular degeneration (AMD)","volume":"102","author":"bis Amoroso","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R16-20250702","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1111\/aos.14554","article-title":"Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-vascular endothelial growth factor therapy using SSOCTA","volume":"99","author":"Told","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"R17-20250702","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1111\/aos.15219","article-title":"Correlation of vascular and fluid-related parameters in neovascular age-related macular degeneration using deep learning","volume":"101","author":"Schranz","year":"2023","journal-title":"Acta Ophthalmol"},{"key":"R18-20250702","doi-asserted-by":"crossref","first-page":"e000369","DOI":"10.1136\/bmjophth-2019-000369","article-title":"Changes in the OCT angiographic appearance of type 1 and type 2 CNV in exudative AMD during anti-VEGF treatment","volume":"4","author":"Faatz","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"R19-20250702","doi-asserted-by":"crossref","first-page":"e925","DOI":"10.1111\/aos.14469","article-title":"AMD management during the COVID-19 pandemic the COVID-19 pandemic","volume":"98","author":"Colantuono","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"R20-20250702","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/11206721211003488","article-title":"Intravitreal injections during COVID-19 outbreak: protective measures, total duration of care and perceived quality of care in a tertiary retina center","volume":"32","author":"Denys","year":"2022","journal-title":"Eur J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T15:00:28Z","timestamp":1751468428000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004444"}},"subtitle":["The ACTOR Study"],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004444","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"type":"print","value":"0275-004X"},{"type":"electronic","value":"1539-2864"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}